Benralizumab

Benralizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD125
Clinical data
Legal status
  • investigational
Identifiers
CAS Number 1044511-01-4 N
ATC code None
ChemSpider none
UNII 71492GE1FX YesY
KEGG D09874 N
Chemical data
Formula C6492H10060N1724O2028S42
Molar mass 146.0 kg/mol
 NYesY (what is this?)  (verify)

Benralizumab (INN) is a monoclonal antibody which is being developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).[1][2]

References

  1. Statement on an Nonproprietary Name adopted by the USAN Counil: Benralizumab
  2. Catley, M. C. (2010). "Asthma & COPD--IQPC's Second Conference". IDrugs : the investigational drugs journal 13 (9): 601–604. PMID 20799138.


This article is issued from Wikipedia - version of the Sunday, February 28, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.